102 related articles for article (PubMed ID: 28277033)
1. Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study.
Espinoza-Zamora JR; Labardini-Méndez J; Sosa-Espinoza A; López-González C; Vieyra-García M; Candelaria M; Lozano-Zavaleta V; Toledano-Cuevas DV; Zapata-Canto N; Cervera E; Dueñas-González A
Expert Opin Investig Drugs; 2017 Apr; 26(4):481-487. PubMed ID: 28277033
[TBL] [Abstract][Full Text] [Related]
2. Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS).
Candelaria M; Burgos S; Ponce M; Espinoza R; Dueñas-Gonzalez A
Ann Hematol; 2017 Nov; 96(11):1825-1832. PubMed ID: 28831600
[TBL] [Abstract][Full Text] [Related]
3. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
Olsen EA; Kim YH; Kuzel TM; Pacheco TR; Foss FM; Parker S; Frankel SR; Chen C; Ricker JL; Arduino JM; Duvic M
J Clin Oncol; 2007 Jul; 25(21):3109-15. PubMed ID: 17577020
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
Duvic M; Talpur R; Ni X; Zhang C; Hazarika P; Kelly C; Chiao JH; Reilly JF; Ricker JL; Richon VM; Frankel SR
Blood; 2007 Jan; 109(1):31-9. PubMed ID: 16960145
[TBL] [Abstract][Full Text] [Related]
5. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
Damaj G; Gressin R; Bouabdallah K; Cartron G; Choufi B; Gyan E; Banos A; Jaccard A; Park S; Tournilhac O; Schiano-de Collela JM; Voillat L; Joly B; Le Gouill S; Saad A; Cony-Makhoul P; Vilque JP; Sanhes L; Schmidt-Tanguy A; Bubenheim M; Houot R; Diouf M; Marolleau JP; Béné MC; Martin A; Lamy T
J Clin Oncol; 2013 Jan; 31(1):104-10. PubMed ID: 23109692
[TBL] [Abstract][Full Text] [Related]
6. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
Dueñas-Gonzalez A; Coronel J; Cetina L; González-Fierro A; Chavez-Blanco A; Taja-Chayeb L
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1433-44. PubMed ID: 25154405
[TBL] [Abstract][Full Text] [Related]
7. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.
Arce C; Pérez-Plasencia C; González-Fierro A; de la Cruz-Hernández E; Revilla-Vázquez A; Chávez-Blanco A; Trejo-Becerril C; Pérez-Cárdenas E; Taja-Chayeb L; Bargallo E; Villarreal P; Ramírez T; Vela T; Candelaria M; Camargo MF; Robles E; Dueñas-González A
PLoS One; 2006 Dec; 1(1):e98. PubMed ID: 17183730
[TBL] [Abstract][Full Text] [Related]
8. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
10. Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma.
Straus DJ; Duvic M; Horwitz SM; Hymes K; Goy A; Hernandez-Ilizaliturri FJ; Feldman T; Wegner B; Myskowski PL
Ann Oncol; 2014 Jan; 25(1):206-10. PubMed ID: 24285015
[TBL] [Abstract][Full Text] [Related]
11. Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.
Duvic M; Kim YH; Zinzani PL; Horwitz SM
Clin Cancer Res; 2017 Jul; 23(14):3552-3556. PubMed ID: 28167509
[No Abstract] [Full Text] [Related]
12. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; He K; Sridhara R; Abraham S; Booth BP; Verbois L; Morse DE; Jee JM; Pope S; Harapanhalli RS; Dagher R; Farrell A; Justice R; Pazdur R
Clin Cancer Res; 2007 Apr; 13(8):2318-22. PubMed ID: 17438089
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
Candelaria M; Gallardo-Rincón D; Arce C; Cetina L; Aguilar-Ponce JL; Arrieta O; González-Fierro A; Chávez-Blanco A; de la Cruz-Hernández E; Camargo MF; Trejo-Becerril C; Pérez-Cárdenas E; Pérez-Plasencia C; Taja-Chayeb L; Wegman-Ostrosky T; Revilla-Vazquez A; Dueñas-González A
Ann Oncol; 2007 Sep; 18(9):1529-38. PubMed ID: 17761710
[TBL] [Abstract][Full Text] [Related]
14. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Sun Y; Straus D; Acosta M; Negro-Vilar A
J Clin Oncol; 2010 Apr; 28(11):1870-7. PubMed ID: 20212249
[TBL] [Abstract][Full Text] [Related]
15. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.
Candelaria M; Herrera A; Labardini J; González-Fierro A; Trejo-Becerril C; Taja-Chayeb L; Pérez-Cárdenas E; de la Cruz-Hernández E; Arias-Bofill D; Vidal S; Cervera E; Dueñas-Gonzalez A
Ann Hematol; 2011 Apr; 90(4):379-87. PubMed ID: 20922525
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.
Coronel J; Cetina L; Pacheco I; Trejo-Becerril C; González-Fierro A; de la Cruz-Hernandez E; Perez-Cardenas E; Taja-Chayeb L; Arias-Bofill D; Candelaria M; Vidal S; Dueñas-González A
Med Oncol; 2011 Dec; 28 Suppl 1():S540-6. PubMed ID: 20931299
[TBL] [Abstract][Full Text] [Related]
18. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
[TBL] [Abstract][Full Text] [Related]
19. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome.
Child F; Ortiz-Romero PL; Alvarez R; Bagot M; Stadler R; Weichenthal M; Alves R; Quaglino P; Beylot-Barry M; Cowan R; Geskin LJ; Pérez-Ferriols A; Hellemans P; Elsayed Y; Phelps C; Forslund A; Kamida M; Zinzani PL
Br J Dermatol; 2016 Jul; 175(1):80-8. PubMed ID: 26836950
[TBL] [Abstract][Full Text] [Related]
20. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
